Try our beta test site
167 studies found for:    "Expanded Access" [STUDY-TYPES] | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
"Expanded Access" [STUDY-TYPES] | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Available Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
Condition: Metastatic Merkel Cell Carcinoma
Intervention: Drug: Avelumab
2 Available Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Condition: Ovarian Cancer
Intervention: Drug: Olaparib tablets
3 Available Omegaven for Compassionate Use in the Treatment of Parenteral Nutrition-Associated Liver Disease
Conditions: Cholestasis;   Liver Diseases
Intervention: Drug: Omegaven
4 Available Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Conditions: Acute Myeloid Leukemia (AML);   FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Intervention: Drug: ASP2215
5 Available Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut
Condition: Recurrent GBM
Intervention: Biological: rindopepimut
6 Available Individual Patient Expanded Access-Glembatumumab Vedotin
Condition: Metastatic gpNMB Expressing Triple Negative Breast Cancer
Intervention: Drug: glembatumumab vedotin
7 Available Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions
Condition: Cancers With NTRK, ROS1, or ALK Gene Fusions
Intervention: Drug: Entrectinib
8 Available Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome
Conditions: Congenital Myasthenic Syndrome;   Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4-Diaminopyridine
9 Available Expanded Access to RXDX-105 for Cancers With RET Alterations
Condition: Cancers With RET Alterations
Intervention: Drug: RXDX-105
10 Available Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma
Condition: Ewing Sarcoma
Intervention: Drug: Ganitumab
11 Available Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer
Condition: Recurrent Ovarian Cancer
Intervention: Drug: Niraparib
12 Available Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion
Conditions: Cancer;   Neurotrophic Tyrosine Kinase, Receptor-related Proteins
Intervention: Drug: larotrectinib
13 Available Dupilumab Compassionate Use Study
Condition: Asthma
Intervention: Drug: Dupilumab
14 Available Study of Cannabidiol for Drug-Resistant Epilepsies
Condition: Drug Resistant Epilepsy
Intervention: Drug: Cannabidiol
15 Available An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC
Conditions: Malignant Neoplasms of Digestive Organs;   Neuroendocrine Tumor;   Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System
Interventions: Drug: 68Ga-DOTATOC;   Procedure: PET/CT
16 Available Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer
Conditions: Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation;   Triple-Negative Breast Cancer
Interventions: Drug: Veliparib;   Drug: Cisplatin;   Drug: Vinorelbine
17 Available Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure
Condition: Heart Decompensation
Intervention: Drug: Levosimendan
18 Available A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease
Condition: CLN2 Disease
Intervention: Drug: BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)
19 Available Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: Ultratrace Iobenguane I131
20 Available Therasphere for Unresectable Primary or Secondary Liver Neoplasia
Conditions: Liver Cancer;   Liver Neoplasms;   HepatoCellular Carcinoma
Intervention: Device: TheraSphere Treatment

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.